A Clinical Trial of Anaprazole for Treating Reflux Esopha... | NCT07010107

NCT07010107

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Anaprazole	Experimental	Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.	Drug: Anaprazole + Rabeprazole placebo
Rabeprazole	Active Comparator	Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.	Drug: Rabeprazole + Anaprazole placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Anaprazole + Rabeprazole placebo	Drug	Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The endoscopic healing rate of reflux esophagitis	The endoscopic healing rate of reflux esophagitis is defined as the proportion of patients with reflux esophagitis who achieve complete mucosal healing. Complete healing is determined by the absence of mucosal breaks upon endoscopic evaluation post-treatment, and the lesion is classified as normal according to the LA classification.	Up to 8 weeks

Secondary Outcomes

Measure	Description	Time Frame
The endoscopic healing rate of reflux esophagitis	The endoscopic healing rate of reflux esophagitis is defined as the proportion of patients with reflux esophagitis who achieve complete mucosal healing. Complete healing is determined by the absence of mucosal breaks upon endoscopic evaluation post-treatment, and the lesion is classified as normal according to the LA classification.	Up to 4 weeks

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

The patients provided voluntary signed informed consent forms.
Aged ≥18 years and ≤75 years old.
Endoscopically diagnosed as reflux esophagitis (LA grade B-D) within 14 days before randomization.

Exclusion Criteria:

Researchers believe that patients with uncontrolled primary diseases are not suitable for clinical trials, particularly those with a history of severe conditions affecting the cardiovascular, nervous, respiratory, hepatic, renal, or other systems.
Patients with concomitant diseases that may affect the esophagus or esophageal motility and, could potentially influence the efficacy evaluation.
Patients with a history of prior surgical procedures that could potentially impact esophageal function, or surgeries.
Patients confirmed to have active peptic ulcers or active upper/lower gastrointestinal bleeding within the last 30 days via esophagogastroduodenoscopy (EGD).
Patients with a history of Zollinger-Ellison syndrome, achalasia of the cardia, secondary esophageal motility disorders, irritable bowel syndrome, inflammatory bowel disease, or other gastrointestinal functional disorders.
Patients with a history of malignant tumor or having received treatment for malignant tumor within 5 years prior to randomization.
Patients with a history of mental illness or a history of drug or alcohol abuse within 12 months prior to screening.
Patients who tested positive for HIV, HBsAg, and/or HCV antibodies during screening.
Patients with malignant tumors or a predisposition to malignancy in the stomach or esophagus.
Patients with abnormal liver function: AST and/or ALT levels ≥2.0×ULN, and/or total bilirubin (TBIL) levels ≥1.5×ULN.
Patients with abnormal renal function: Serum creatinine levels ≥1.5×ULN, blood urea or blood urea nitrogen levels ≥1.5×ULN.
Patients with clinically significant ECG abnormalities, including QTc interval prolongation (QTcF ≥450 ms for men and QTcF ≥470 ms for women).
Patients with poorly controlled diabetes or hypertension.
Patients who were unable to undergo esophagogastroduodenoscopy (EGD).
Patients with a known allergy to the components or ingredients of Anaprazole or Rabeprazole.
Patients who had used proton pump inhibitors at therapeutic doses within 14 days prior to randomization.
Patients who had used therapeutic doses of other drugs for treating acid reflux within 7 days prior to randomization.
Patients required to continue receiving non-steroidal anti-inflammatory drugs (NSAIDs), systemic glucocorticoids, or clopidogrel during the trial period.
Patients whose assessment may be affected by alcohol, drug, or medication withdrawal during the study.
Pregnant or lactating women, as well as patients planning to conceive within 30 days before randomization and up to 6 months following the trial completion.
Patients who had participated in other drug clinical trials within 3 months prior to randomization.
Patients with other conditions deemed by the researchers as unsuitable for participation in this clinical trial.

ID	Term
D004941	Esophagitis
D004935	Esophageal Diseases
D005767	Gastrointestinal Diseases
D004066	Digestive System Diseases

ID	Term
D053799	2-Pyridinylmethylsulfinylbenzimidazoles
D013454	Sulfoxides
D013457	Sulfur Compounds
D009930	Organic Chemicals